RT Journal Article
T1 Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
A1 Damasceno, Daniela
A1 Almeida, Julia
A1 Teodosio, Cristina
A1 Sanoja-Flores, Luzalba
A1 Mayado, Andrea
A1 Pérez-Pons, Alba
A1 Puig, Noemi
A1 Arana, Paula
A1 Paiva, Bruno
A1 Solano, Fernando
A1 Romero, Alfonso
A1 Matarraz, Sergio
A1 van den Bossche, Wouter B L
A1 Flores-Montero, Juan
A1 Durie, Brian
A1 van Dongen, Jacques J M
A1 Orfao, Alberto
K1 FcεRI monocytes
K1 MGUS
K1 bone markers
K1 immunosenescence
K1 inflammatory cytokines
K1 monocytes
K1 multiple myeloma
K1 plasma cell neoplasms
K1 tumor microenvironment
AB Monocyte/macrophages have been shown to be altered in monoclonal gammopathy of undetermined significance (MGUS), smoldering (SMM) and active multiple myeloma (MM), with an impact on the disruption of the homeostasis of the normal bone marrow (BM) microenvironment. We investigated the distribution of different subsets of monocytes (Mo) in blood and BM of newly-diagnosed untreated MGUS (n = 23), SMM (n = 14) and MM (n = 99) patients vs. healthy donors (HD; n = 107), in parallel to a large panel of cytokines and bone-associated serum biomarkers. Our results showed normal production of monocyte precursors and classical Mo (cMo) in MGUS, while decreased in SMM and MM (p ≤ 0.02), in association with lower blood counts of recently-produced CD62L+ cMo in SMM (p = 0.004) and of all subsets of (CD62L+, CD62L- and FcεRI+) cMo in MM (p ≤ 0.02). In contrast, intermediate and end-stage non-classical Mo were increased in BM of MGUS (p ≤ 0.03), SMM (p ≤ 0.03) and MM (p ≤ 0.002), while normal (MGUS and SMM) or decreased (MM; p = 0.01) in blood. In parallel, increased serum levels of interleukin (IL)1β were observed in MGUS (p = 0.007) and SMM (p = 0.01), higher concentrations of serum IL8 were found in SMM (p = 0.01) and MM (p = 0.002), and higher serum IL6 (p = 0.002), RANKL (p = 0.01) and bone alkaline phosphatase (BALP) levels (p = 0.01) with decreased counts of FcεRI+ cMo, were restricted to MM presenting with osteolytic lesions. This translated into three distinct immune/bone profiles: (1) normal (typical of HD and most MGUS cases); (2) senescent-like (increased IL1β and/or IL8, found in a minority of MGUS, most SMM and few MM cases with no bone lesions); and (3) pro-inflammatory-high serum IL6, RANKL and BALP with significantly (p = 0.01) decreased blood counts of immunomodulatory FcεRI+ cMo-, typical of MM presenting with bone lesions. These results provide new insight into the pathogenesis of plasma cell neoplasms and the potential role of FcεRI+ cMo in normal bone homeostasis.
SN 2072-6694
YR 2021
FD 2021-03-22
LK https://hdl.handle.net/10668/27498
UL https://hdl.handle.net/10668/27498
LA en
DS RISalud
RD Apr 4, 2025